Wellbutrin (bupropion) is not a serotonin reuptake inhibitor. It belongs to a completely different class of antidepressants called norepinephrine-dopamine reuptake inhibitors (NDRIs). In lab testing, bupropion’s effect on serotonin was negligible even at the highest concentrations tested. This distinction matters because it explains why Wellbutrin has a noticeably different side effect profile than SSRIs like Prozac, Zoloft, or Lexapro.
How Wellbutrin Actually Works
Instead of targeting serotonin, bupropion blocks the reuptake of two other brain chemicals: norepinephrine and dopamine. Reuptake is the process where nerve cells reabsorb a neurotransmitter after releasing it. By slowing that recycling process, bupropion keeps more norepinephrine and dopamine active in the brain for longer. Norepinephrine plays a role in alertness, energy, and concentration, while dopamine is involved in motivation, pleasure, and reward.
A comprehensive review in The Primary Care Companion to The Journal of Clinical Psychiatry confirmed that bupropion “is devoid of clinically significant serotonergic effects or direct effects on postsynaptic receptors.” It doesn’t trigger the release of other neurotransmitters and doesn’t bind to unrelated receptor sites, which keeps its pharmacological footprint relatively narrow.
Why This Distinction Matters for Side Effects
Many of the side effects people associate with antidepressants are driven specifically by serotonin activity. Sexual dysfunction is probably the most well-known example. SSRIs like sertraline, paroxetine, and fluoxetine are the antidepressants most likely to cause problems with libido, arousal, or orgasm. Because bupropion doesn’t touch serotonin, it carries the lowest rate of sexual side effects among common antidepressants. Some prescribers even add bupropion to an existing SSRI regimen specifically to counteract sexual side effects the SSRI is causing.
Weight is another area where the two classes diverge. SSRIs are often associated with gradual weight gain over time. Bupropion tends to go in the opposite direction. In clinical studies of Wellbutrin XL at doses of 150 to 300 mg per day, 23% of patients lost five pounds or more, while only 11% gained that much. Studies of the sustained-release version showed even sharper numbers: at 300 mg, 14% lost more than five pounds, with only 3% gaining that amount.
Bupropion does have its own unique risks, though. It lowers the seizure threshold more than most antidepressants. At recommended doses (up to 450 mg per day), the seizure rate is roughly 4 in 1,000, which is about four times higher than other antidepressants on the market. That risk jumps dramatically at higher doses, nearly tenfold between 450 and 600 mg per day.
Who Should Not Take Wellbutrin
Because of the seizure risk, bupropion is not appropriate for people with a seizure disorder or a current or past diagnosis of bulimia or anorexia nervosa. Patients with eating disorders showed a higher incidence of seizures in clinical trials. It’s also contraindicated for anyone going through abrupt withdrawal from alcohol or sedatives, since both of those situations already lower the seizure threshold.
Bupropion cannot be combined with MAO inhibitors, and there needs to be at least a 14-day gap between stopping an MAO inhibitor and starting Wellbutrin. It also should not be taken alongside other bupropion-containing products like Zyban (used for smoking cessation), since doubling up increases the dose and the seizure risk along with it.
What Wellbutrin Is Approved to Treat
The FDA has approved Wellbutrin XL for two conditions: major depressive disorder and the prevention of seasonal depressive episodes in people diagnosed with seasonal affective disorder. For both, the typical starting dose is 150 mg once daily in the morning, with an increase to 300 mg after several days if tolerated. The morning timing is intentional, since bupropion’s stimulating effect on norepinephrine and dopamine can cause insomnia if taken too late in the day.
Bupropion is also widely prescribed off-label for attention difficulties, smoking cessation (under the brand name Zyban), and as a weight management aid in combination with naltrexone.
Pairing Wellbutrin With an SSRI
Because bupropion and SSRIs work on entirely separate neurotransmitter systems, they’re frequently prescribed together. This combination is one of the most common strategies for treatment-resistant depression, where a single antidepressant hasn’t been enough. Randomized controlled trials have shown that adding bupropion to an existing antidepressant improves depressive symptoms and fatigue. The combination may be as effective as adding an antipsychotic medication, with fewer long-term side effects.
The pairing also makes pharmacological sense. An SSRI boosts serotonin while bupropion boosts norepinephrine and dopamine, covering three major neurotransmitter systems simultaneously. For patients who respond partially to an SSRI but still feel flat, unmotivated, or fatigued, bupropion can address exactly those residual symptoms. The combination also helps offset SSRI-driven sexual side effects and weight gain, two of the most common reasons people stop taking their antidepressant.